Yanhong Zhang*, Hong Wang, Lina Xie, De Wang, Xiaoqian Zhang, Wei Ma
Department of Respiratory Medicine, Zibo Mining Group Co. Ltd. Central Hospital, Zibo 255120, Shandong Province, China
Objective: To investigate the changes and significance of serum levels of lemur tyrosine kinase 3 (LMTK-3), insulin-like growth factor binding protein 7 (IGFBP-7), serum cytokeratin 19 (CYFRA21-1), and soluble interleukin-2 receptor (SIL-2R) in patients with advanced non-small cell lung cancer (NSCLC) before and after chemotherapy.
Methods: 42 patients with advanced NSCLC admitted to our hospital from June 2018 to September 2019 were randomly selected as the study group, and 42 normal subjects who had physical examinations in our hospital at the same time were selected as the control group. The patients in the study group were treated with gemcitabine combined with nedaplatin for at least 2 cycles. The basic clinical data of the two groups were compared, and the clinical effect of the study group after chemotherapy was compared. The serum levels of LMTK-3, IGFBP-7, CYFRA21-1, and SIL-2R in the two groups were compared, and the serum levels of LMTK-3, IGFBP-7, CYFRA21-1, and SIL-2R in the study groups with different chemotherapy results were observed.
Results: After chemotherapy, the RR and DCR of the study group were 26.19% and 61.90%, respectively. Compared with levels before treatment, the levels of lmtk-3, CYFRA21-1, and SIL-2R in the study group were significantly lower and the levels of IGFBP-7 were significantly higher than those in the control group (P<.05). According to the effects of chemotherapy, the patients were divided into a PR group (11 cases) and an SD + PD group (31 cases). Compared with levels before chemotherapy, the levels of LMTK-3, CYFRA21-1, and SIL-2R in the PR group were significantly lower, and the levels of IGFBP-7 were significantly higher (P<.05). The serum levels of LMTK-3, CYFRA21-1, and SIL-2R in the SD + PD group decreased, while IGFBP-7 increased; however, the difference was not statistically significant (P>.05).
Conclusion: Gemcitabine combined with nedaplatin can significantly reduce the serum levels of LMTK-3, CYFRA21-1, and SIL-2R and increase the level of IGFBP-7 in patients with NSCLC in the late stages of chemotherapy. These can be used as important indicators of chemotherapy efficacy, which is highly significant for the evaluation of chemotherapy efficacy.
Advanced NSCLC, CYFRA21-1, IGFBP-7, LMTK-3, SIL-2R.